You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》药明康德(02359.HK)旗下未有盈利生物公司申请上市
阿思达克 08-17 10:48
未有盈利生物公司JW (Cayman) Therapeutics向联交所递交上市申请,以筹集资金作研发推广活动,以及其他潜在收购等,由高盛和瑞银担任联席保荐人。该公司是一家临床阶段细胞治疗平台公司,由Juno与药明康德 (02359.HK)通过其全资附属公司上海药明於2016年成立。

国家药监局已於2020年6月受理审查公司将relma-cel用作DLBCL三线疗法的新药申请。Relma-cel有望成为中国首个获批的一类生物制品CAR-T疗法,并有望成为同类最佳CAR-T疗法。

公司亦有其他候选产品,包括JWCAR129是以在MM中表达的BCMA为靶点的CAR-T产品;下一代抗CD19候选产品;JWATM203是临床前阶段及潜在同类首创以AFP为靶点治疗HCC的TCRmT细胞疗法;JWATM204是以GPC3为靶点的新型T细胞疗法候选产品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account